BSC
CRSP icon

BOLTON SECURITIES CORPORATION’s CRISPR Therapeutics CRSP Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$91.1K Hold
1,647
– – ﹤0.01% 1157
2026
Q2 		$89.8K Sell
1,647
-329
-17% -$17.3K ﹤0.01% 1147
2026
Q1 		$94K Buy
+1,976
New +$104K ﹤0.01% 1043
2025
Q3 		$120K Buy
+1,847
New +$106K 0.01% 898
2025
Q1 		$88.5K Buy
+2,602
New +$110K 0.01% 910

Other funds holding CRSP

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's CRSP Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 1,647 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

BOLTON SECURITIES CORPORATION first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $120K in Q3 2025. 326 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • BOLTON SECURITIES CORPORATION held 1,647 shares of CRISPR Therapeutics worth $91.1K as of Q3 2026.
  • BOLTON SECURITIES CORPORATION left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #1157 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • BOLTON SECURITIES CORPORATION's CRISPR Therapeutics position peaked at $120K in Q3 2025.
  • 326 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.